Tripotassium dicitrato bismuthate/tetracycline/metronidazole

Drug Profile

Tripotassium dicitrato bismuthate/tetracycline/metronidazole

Alternative Names: Biskalcitrate potassium 140mg/metronidazole 125mg/tetracycline hydrochloride 125mg; Bismuth subcitrate/metronidazole/tetracycline - Adare Pharmaceuticals; Bismuth-based triple therapy - Adare Pharmaceuticals; Bismuth/metronidazole/tetracycline; Helicide; Helizide; Pylera

Latest Information Update: 10 Apr 2015

Price : $50

At a glance

  • Originator Axcan Pharma
  • Developer Adare Pharmaceuticals; Aptalis
  • Class Cytoprotectives; Helicobacter pylori eradication therapies; Nitroimidazoles; Organometallic compounds; Tetracyclines
  • Mechanism of Action DNA synthesis inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Helicobacter infections

Most Recent Events

  • 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
  • 01 Apr 2015 Launched for Helicobacter infections (Combination therapy) in Germany, Kuwait, Lebanon, Poland and Qatar prior to April 2015 (PO)
  • 01 Apr 2015 No recent reports on development identified - Registered for Helicobacter infections (Combination therapy) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top